Cochrane · systematic review · CD011290
Interventions for eye movement disorders due to acquired brain injury
Rowe, FJ, Hanna, K, Evans, JR, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
Eyes and VisionAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
8
current version
GRADE rated
6
No studies
2
Included studies
NR
No studies 2 · 25%Ungraded 0 · 0%Very low 3 · 37.5%Low 3 · 37.5%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Botulinum toxin versus observation
Population: people with sixth nerve palsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Improvement in ocular motility (ocular alignment ≤ 10 prism dioptres). Botulinum toxin vs observation | RR 1.19 [0.96, 1.48] | 1 study · 47 participants | Low Downgraded: risk of bias, imprecision |
Achievement of binocular single vision (fusion and stereopsis present). Botulinum toxin vs observation | RR 1.19 [0.96, 1.48] | 1 study · 47 participants | Low Downgraded: risk of bias, imprecision |
Improvement in functional ability Botulinum toxin vs observation | no estimate extracted | NR | No studies |
Quality of life Botulinum toxin vs observation | no estimate extracted | NR | No studies |
Adverse events. Botulinum toxin vs observation | no estimate extracted | 1 study · 47 participants | Low Downgraded: risk of bias, imprecision |
Pharmacological treatment
Population: people with acquired nystagmus
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Gabapentin up to 900 mg/day) versus baclofen (up to 30 mg/day). | no estimate extracted | 1 study · 21 participants | Very low Downgraded: risk of bias, imprecision |
3,4‐DAP (20 mg, single dose) versus placebo. Assessments made 30 minutes after taking the drug or placebo | no estimate extracted | 1 study · 17 participants | Very low Downgraded: risk of bias, imprecision |
4‐AP (10 mg, single dose) versus 3,4‐DAP (10 mg, single dose) Assessments made at 45 and 90 minutes after taking the drug | no estimate extracted | 1 study · 8 participants | Very low Downgraded: risk of bias, imprecision |